Member Biography


Milan Radovich

Milan Radovich, Ph.D.

980 W. Walnut St.
Walther Hall, R3 223
Indianapolis, IN 46202

Phone: (317) 278-0189
Fax: (317) 274-0396

Research Program Membership

Assistant Professor
Department of Surgery
Division of General Surgery
IU School of Medicine

Assistant Professor
Department of Medical and Molecular Genetics

My laboratory is focused on the use of next-generation sequencing technology in translational oncology. In particular, we are using this technology to identify novel drug targets to better treat triple-negative breast cancer, inflammatory breast cancer, and thymic malignancies. We are also using the technology to identify novel mutations that can help explain the causation of these diseases. Our work is very integrated into the clinical enterprise of the Indiana University Simon Cancer Center, and actively works with a team of clinicians to recruit patient samples and to apply findings to correlative studies within clinical trials. Current research revolves around three main projects: Project 1. Triple-negative breast cancer and the normal breast: We have recently sequenced and analyzed the entire transcriptomes of triple-negative breast cancers and normal breast tissues. Our normal controls were derived from microdissected ductal epithelium collected from the unique resource of the Susan G. Komen Tissue Bank at the IU Simon Cancer Center. This data has revealed transcriptional differences that have leant understanding into why previous targeted therapies in triple-negative breast cancer have failed in clinical trial, and also has identified new targets that are now active in drug development. We are also identifying novel mutations that are lending clues into the possible causation and chemotherapeutic sensitivity of triple-negative breast cancers. Project 2. Inflammatory Breast Cancer: Our newest project is studying the transcriptomes of inflammatory breast cancers (IBC), a rare and aggressive breast cancer that carries a poor prognosis. This disease is characterized by the dissemination of tumor cells into the subdermal lymphatics leading to an inflammatory response. In partnership with the IBC Research Foundation and NYU, we are using next-generation RNA sequencing to understand the key gene expression perturbations and mutational events that comprises this disease. In addition, we are leveraging our expertise in the transcriptomics of the normal breast to understand the key genes that differentiates IBC from normal breast tissue. Project 3. Thymic Malignancies: Thymomas and thymic carcinomas are rare diseases with only ~500 cases in the US per year. The Indiana University Simon Cancer Center is a world leader in thymic malignancies and cares for a large proportion of affected patients. Using the unique tissue resources available at our institution for this disease, we have recently completed the RNA-sequencing of a cohort of thymic malignancies. Preliminary data has demonstrated that gene expression profiling can perfectly delineate the WHO subtypes for thymomas, which has traditionally been difficult to assess using standard histopathologic features. Further, preliminary data is identifying recurrent mutations in key driver genes that may lead to understanding the causation and possible treatment of this rare disease. Using data derived from these projects, we are actively translating these findings into further downstream pre-clinical investigations and clinical applications including: further elucidation of the intrinsic tumor biology, development of diagnostics, and development of novel therapeutics.

Importing from PubMed - Please Wait...

More Publications »